These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia. Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834 [No Abstract] [Full Text] [Related]
5. Long-term durability of molecular and chimerism responses in patients treated with imatinib for chronic myeloid leukemia relapse after allogeneic transplantation. Martín-Palanco V; Martínez F; Arqueros V; Torres A; Román-Gómez J Eur J Haematol; 2011 Aug; 87(2):182-5. PubMed ID: 21762210 [No Abstract] [Full Text] [Related]
6. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis. Radojkovic M; Ristic S; Pavlovic S; Colovic M Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403 [TBL] [Abstract][Full Text] [Related]
7. Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia. Champlin RE; Kantarjian H Clin Adv Hematol Oncol; 2003 Jul; 1(7):398-400. PubMed ID: 16258420 [No Abstract] [Full Text] [Related]
8. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G; Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599 [TBL] [Abstract][Full Text] [Related]
9. [Chronic myeloid leukemia--treatment]. Stoetzer OJ; Hentrich M; Salat C Dtsch Med Wochenschr; 2002 Dec; 127(49):2621-4. PubMed ID: 12469275 [No Abstract] [Full Text] [Related]
10. Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias. Tiribelli M; Marin L; Calistri E; Geromin A; Damiani D; Fanin R Bone Marrow Transplant; 2004 Nov; 34(9):827-8. PubMed ID: 15334052 [No Abstract] [Full Text] [Related]
12. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript. Li X; Yang J; Chen X; Liu J; Li H; Zheng J; He Y; Chen Z; Huang S Cancer Genet Cytogenet; 2007 Jul; 176(2):166-8. PubMed ID: 17656262 [TBL] [Abstract][Full Text] [Related]
13. [Molecular monitoring: an essential component of the treatment for chronic myeloid leukemia]. Lange T; Pelz-Ackermann O; Burkhardt R; Niederwieser D Dtsch Med Wochenschr; 2006 Oct; 131(43):2390-4. PubMed ID: 17054054 [No Abstract] [Full Text] [Related]
14. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment. Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370 [No Abstract] [Full Text] [Related]
15. Trends in the management of chronic myelogenous leukemia. Kantarjian H J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S41-5. PubMed ID: 16280112 [No Abstract] [Full Text] [Related]
16. Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up. Moser AM; Manor E; Narkis G; Kapelushnik J Cancer Genet Cytogenet; 2006 Oct; 170(1):54-7. PubMed ID: 16965955 [TBL] [Abstract][Full Text] [Related]
17. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522 [TBL] [Abstract][Full Text] [Related]
18. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience]. Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775 [TBL] [Abstract][Full Text] [Related]
19. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia]. Minami Y; Naoe T Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024 [TBL] [Abstract][Full Text] [Related]
20. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia. Dvorak P; Hruba M; Subrt I Leuk Res; 2009 Jun; 33(6):860-1. PubMed ID: 18977531 [No Abstract] [Full Text] [Related] [Next] [New Search]